

- (a) an amino acid sequence comprising residues +1 to +371 of SEQ ID NO:2;
- (b) an amino acid sequence comprising residues +2 to +371 of SEQ ID NO:2; and
- (c) an amino acid sequence comprising residues +23 to +371 of SEQ ID NO:2.

(a). 25. (New) The isolated polypeptide of claim 24 which comprises amino acid sequence

(b). 26. (New) The isolated polypeptide of claim 24 which comprises amino acid sequence

Gu (c). 27. (New) The isolated polypeptide of claim 24 which comprises amino acid sequence

28. (New) The isolated polypeptide of claim 24 wherein said amino acid sequence further comprises a heterologous polypeptide sequence.

---

29. (New) The isolated polypeptide of claim 28 wherein said heterologous polypeptide sequence is that of the Fc domain of immunoglobulin.

30. (New) A composition comprising the isolated polypeptide of claim 24 and a pharmaceutically acceptable carrier.

31. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence of the full length polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641;

(b) an amino acid sequence of the full length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209691 or 209641; and

(c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641.

32. (New) The isolated polypeptide of claim 31 which comprises amino acid sequence (a).

33. (New) The isolated polypeptide of claim 31 which comprises amino acid sequence (b).

34. (New) The isolated polypeptide of claim 31 which comprises amino acid sequence (c).

35. (New) The isolated polypeptide of claim 31 wherein said amino acid sequence further comprises a heterologous polypeptide sequence.

36. (New) The isolated polypeptide of claim 35 wherein said heterologous polypeptide sequence is that of the Fc domain of immunoglobulin.

91 37. (New) A composition comprising the isolated polypeptide of claim 31 and a pharmaceutically acceptable carrier.

38. (New) The isolated polypeptide of claim 24 comprising a heterodimer.

39. (New) The isolated polypeptide of claim 31 comprising a heterodimer.

40. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

Sub B1 (a) an amino acid sequence comprising residues m to 371 of SEQ ID NO:2, where m is an integer in the range of +2 to +370;

(b) an amino acid sequence comprising residues 1 to n of SEQ ID NO:2, where n is an integer in the range of +2 to +371; and

(c) an amino acid sequence comprising residues m to n of SEQ ID NO:2, where m is an integer in the range of +2 to +370 and n is an integer in the range of +2 to +371.

Sub E2 41. (New) The isolated polypeptide of claim 40, which comprises amino acid sequence (a).

42. (New) The isolated polypeptide of claim 40, which comprises amino acid sequence (b).

Sub E2  
43. (New) The isolated polypeptide of claim 40, which comprises amino acid sequence (c).

---

44. (New) The isolated polypeptide of claim 40 wherein said amino acid sequence further comprises a heterologous polypeptide sequence.

45. (New) The isolated polypeptide of claim 44 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

C1  
46. (New) A composition comprising the isolated polypeptide of claim 40 and a pharmaceutically acceptable carrier.

---

Sub B  
47. (New) The isolated polypeptide of claim 42, wherein said amino acid sequence comprises amino acid residues +1 to +231.

---

48. (New) The isolated polypeptide of claim 43, wherein said amino acid sequence comprises amino acid residues selected from the group consisting of:

- (a) amino acid residues +23 to +231 of SEQ ID NO:2;
- (b) amino acid residues +23 to +225 of SEQ ID NO:2;
- (c) amino acid residues +198 to +204 of SEQ ID NO:2;
- (d) amino acid residues +226 to +260 of SEQ ID NO:2 and
- (e) amino acid residues +261 to +268 of SEQ ID NO:2.

49. (New) The isolated polypeptide of claim 43, wherein said amino acid sequence comprises amino acid residues selected from the group consisting of:

- (a) amino acid residues +22 to +29 of SEQ ID NO:2;
- (b) amino acid residues +48 to +56 of SEQ ID NO:2;
- (c) amino acid residues +62 to +73 of SEQ ID NO:2;
- (d) amino acid residues +78 to +85 of SEQ ID NO:2;

- (e) amino acid residues +88 to +95 of SEQ ID NO:2;
  - (f) amino acid residues +99 to +105 of SEQ ID NO:2;
  - (g) amino acid residues +118 to +126 of SEQ ID NO:2;
  - (h) amino acid residues +139 to +146 of SEQ ID NO:2;
  - (i) amino acid residues +151 to +169 of SEQ ID NO:2;
  - (j) amino acid residues +188 to +206 of SEQ ID NO:2;
  - (k) amino acid residues +208 to +231 of SEQ ID NO:2;
  - (l) amino acid residues +264 to +271 of SEQ ID NO:2;
  - (m) amino acid residues +286 to +293 of SEQ ID NO:2;
  - (n) amino acid residues +300 to +313 of SEQ ID NO:2;
  - (o) amino acid residues +317 to +342 of SEQ ID NO:2;
  - (p) amino acid residues +347 to +353 of SEQ ID NO:2; and
  - (q) amino acid residues +363 to +369 of SEQ ID NO:2.
- 

*G1* *Sub 2*  
*D2* 50. (New) An isolated polypeptide comprising at least 30 contiguous amino acid residues of SEQ ID NO:2.

---

51. (New) An isolated polypeptide comprising at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209691 or 209641.

---

*Sub E5* 52. (New) The isolated polypeptide of claim 50 further comprising at least 50 contiguous amino acid residues of SEQ ID NO:2.

---

53. (New) The isolated polypeptide of claim 51 further comprising at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209691 or 209641.

54. (New) The isolated polypeptide of claim 50 wherein said polypeptide regulates the differentiation and/or proliferation of cells.

55. (New) The isolated polypeptide of claim 50 wherein said polypeptide activates proliferation or differentiation of immune cells.

56. (New) The isolated polypeptide of claim 50 wherein said polypeptide increases proliferation or differentiation of hematopoietic cells.

---

57. (New) The isolated polypeptide of claim 50 wherein said polypeptide modulates hemostatic activity.

---

58. (New) The isolated polypeptide of claim 50 wherein said polypeptide modulates inflammation.

---

59. (New) The isolated polypeptide of claim 51 wherein said polypeptide regulates the differentiation and/or proliferation of cells.

---

60. (New) The isolated polypeptide of claim 51 wherein said polypeptide activates proliferation or differentiation of immune cells.

---

61. (New) The isolated polypeptide of claim 51 wherein said polypeptide increases proliferation or differentiation of hematopoietic cells.

---

62. (New) The isolated polypeptide of claim 51 wherein said polypeptide modulates hemostatic activity.

---

63. (New) The isolated polypeptide of claim 51 wherein said polypeptide modulates inflammation.

---

64. (New) An isolated polypeptide comprising a first amino acid sequence 90% or more identical to a second amino acid sequence selected from the group consisting of:

- (a) amino acids +1 to +371 of SEQ ID NO:2;
- (b) amino acids +2 to +371 of SEQ ID NO:2;
- (c) amino acids +23 to +371 of SEQ ID NO:2; and
- (d) amino acids +23 to +231 of SEQ ID NO:2

wherein percent identity is calculated using FASTDB with the parameters set such that percentage of identity is calculated over the full length of the reference amino acid

sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference amino acid sequence are allowed.

65. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (a).

66. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (b).

67. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (c).

68. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (d).

69. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (a).

70. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (b).

71. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (c).

72. (New) The isolated polypeptide of claim 64 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (d).

73. (New) The isolated polypeptide of claim 64 wherein said amino acid sequence further comprises a heterologous polypeptide sequence.

74. (New) The isolated polypeptide of claim 73 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

75. (New) A composition comprising the isolated polypeptide of claim 64 and a pharmaceutically acceptable carrier.

*See 64*  
76. (New) An isolated polypeptide comprising a first amino acid sequence 90% or more identical to a second amino acid sequence selected from the group consisting of:

(a) an amino acids sequence of the full length polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641;

(b) an amino acids sequence of the full length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209691 or 209641;

(c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641; and

(d) an amino acid sequence of the soluble extracellular domain of the polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641

*Gu*  
wherein percent identity is calculated using FASTDB with the parameters set such that percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference amino acid sequence are allowed.

77. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (a).

78. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (b).

79. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (c).

80. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 90% identical to said second amino acid sequence (d).

81. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (a).

82. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (b).

83. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (c).

84. (New) The isolated polypeptide of claim 76 wherein said first amino acid sequence is 95% identical to said second amino acid sequence (d).

85. (New) The isolated polypeptide of claim 76 wherein said amino acid sequence further comprises a heterologous polypeptide sequence.

86. (New) The isolated polypeptide of claim 85 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

87. (New) A composition comprising the isolated polypeptide of claim 76 and a pharmaceutically acceptable carrier.

88. (New) An isolated polypeptide encoded by a nucleic acid molecule comprising a polynucleotide which hybridizes to the complement of the polynucleotide set forth in SEQ ID NO:1 wherein said hybridization occurs under conditions consisting essentially of hybridization in a buffer consisting essentially of 50% formamide, 5X SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 ug/ml denatured, sheared salmon sperm DNA at 42°C and wash in a solution consisting essentially of 0.1X SSC at 65°C.

Sub E9 89. (New) The isolated polypeptide of claim 88 which regulates the differentiation and/or proliferation of cells.

90. (New) The isolated polypeptide of claim 88, which binds an antibody specific for a polypeptide comprising amino acid sequence of SEQ ID NO:2.



91. (New) The isolated polypeptide of claim 88 comprising a heterologous polypeptide sequence.

92. (New) The isolated polypeptide of claim 91 wherein said heterologous polypeptide sequence is that of the Fc domain of immunoglobulin.

93. (New) A composition comprising the isolated polypeptide of claim 88 and a pharmaceutically acceptable carrier.

94. (New) An isolated polypeptide encoded by a nucleic acid molecule comprising a polynucleotide which hybridizes to the cDNA in ATCC Deposit No. 209691 or 209641 wherein said hybridization occurs under conditions consisting essentially of hybridization in a buffer consisting essentially of 50% formamide, 5X SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 ug/ml denatured, sheared salmon sperm DNA at 42°C and wash in a solution consisting essentially of 0.1X SSC at 65°C.

*Ch* *Sub E10* 95. (New) The isolated polypeptide of claim 94 which regulates the differentiation and/or proliferation of cells.

---

96. (New) The isolated polypeptide of claim 94, which binds an antibody specific for a polypeptide comprising amino acid sequence encoded by the cDNA in ATCC Deposit No. 209691 or 209641.

97. (New) The isolated polypeptide of claim 94 comprising a heterologous polypeptide sequence.

98. (New) The isolated polypeptide of claim 97 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

99. (New) A composition comprising the isolated polypeptide of claim 94 and a pharmaceutically acceptable carrier.

100. (New) An isolated polypeptide comprising an amino acid sequence, wherein, except for one to thirty amino acid substitutions, said amino acid sequence is identical to contiguous amino acid residues selected from the group consisting of:

- Sub D5
- (a) amino acid residues +1 to +371 of SEQ ID NO:2;
  - (b) amino acid residues +2 to +371 of SEQ ID NO:2;
  - (c) amino acid residues +23 to +371 of SEQ ID NO:2;
  - (d) amino acid residues +1 to +231 of SEQ ID NO:2; and
  - (e) amino acid residues +23 to +231 of SEQ ID NO:2.
- Cr  
G1

101. (New) An isolated polypeptide comprising an amino acid sequence, wherein, except for one to thirty amino acid substitutions, said amino acid sequence is identical to contiguous amino acid residues selected from the group consisting of:

- (a) an amino acid sequence of the full length polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641;
- (b) an amino acid sequence of the full length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209691 or 209641;
- (c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641;
- (d) an amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641; and
- (e) an amino acid sequence of the soluble extracellular domain of the polypeptide encoded by the cDNA in ATCC Deposit No. 209691 or 209641.--

#### Remarks

Claims 2-12, 14-16 and 20-21 have been canceled, and new claims 24-101 have been added. Support for the newly added claims is found throughout the specification as filed.

Particularly, support for claims 24-27 and 31-34 can be found, for example, at page 8, fourth full paragraph; page 9, third full paragraph; page 46, line 6 and page 73, lines 10-11. Support for claims 28-30, 35-37, 44-46, 73-75, 85-87, 91-93 and 97-99 can be found, for example, at page 69, third full paragraph through page 70; and page 166, second full paragraph. In addition, support for claims 38 and 39 can be found, for example, at page 77, first and second full paragraphs. Support for claims 40(a) and 41 can be found, for example, at page 40, second full paragraph; further, support for claims 40(b), 42 and 47 can be found,